Randomized, Controlled, Multi-center Trial: Comparing the Safety and Efficacy of DA-9701 and Itopride Hydrochloride in Patients With Functional Dyspepsia
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Choi, Myung-Gyu | - |
dc.contributor.author | Rhee, Poong-Lyul | - |
dc.contributor.author | Park, Hyojin | - |
dc.contributor.author | Lee, Oh Young | - |
dc.contributor.author | Lee, Kwang Jae | - |
dc.contributor.author | Choi, Suck Chei | - |
dc.contributor.author | Seol, Sang Young | - |
dc.contributor.author | Chun, Hoon Jai | - |
dc.contributor.author | Rew, Jong-Sun | - |
dc.contributor.author | Lee, Dong Ho | - |
dc.contributor.author | Song, Geun Am | - |
dc.contributor.author | Jung, Hwoon Yong | - |
dc.contributor.author | Jeong, Hyung Yong | - |
dc.contributor.author | Sung, In Kyung | - |
dc.contributor.author | Lee, Joon Seong | - |
dc.contributor.author | Lee, Soo Teik | - |
dc.contributor.author | Kim, Sung Kook | - |
dc.contributor.author | Shin, Yong Woon | - |
dc.date.accessioned | 2022-07-15T22:01:57Z | - |
dc.date.available | 2022-07-15T22:01:57Z | - |
dc.date.created | 2021-05-12 | - |
dc.date.issued | 2015-07 | - |
dc.identifier.issn | 2093-0879 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/156838 | - |
dc.description.abstract | Background/Aims Therapies of functional dyspepsia (FD) are limited. DA-9701 is a novel prokinetic agent formulated with Pharbitis semen and Corydalis Tuber. We aimed to assess the efficacy of DA-9701 compared with itopride in FD patients. Methods Patients with FD. randomly received either itopride 50 mg or DA-9701 30 mg t.i.d after a 2-week baseline period. After 4 weeks of treatment, 2 primary efficacy endpoints were analyzed: the change from baseline in composite score of the 8 dyspeptic symptoms and the overall treatment effect. Impact on patients' quality of life was assessed using the Nepean Dyspepsia Index (NI) questionnaire. Results We randomly assigned 464 patients with 455 having outcome data. The difference of the composite score change of the 8 symptoms between the 2 groups was 0.62, indicating that DA-9701 was not inferior to itopride. The overall treatment effect response rate was not different between the groups. When responder was defined as >= 5 of the 7 Likert scale, responder rates were 37% of DA-9701 and 36% of itopride group. Patients receiving DA-9701 experienced similar mean percentage of days with adequate relief during the 4-week treatment period compared with those receiving itopride (56.8% vs 59.1%). Both drugs increased the NDI score of 5 domains without any difference in change of the NDI score between the groups. The safety profile of both drugs was comparable. Conclusions DA-9701 significantly improves symptoms in patients with FD. DA-9701 showed non-inferior efficacy to itopride with comparable safety. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | KOREAN SOC NEUROGASTROENTEROLOGY & MOTILITY | - |
dc.title | Randomized, Controlled, Multi-center Trial: Comparing the Safety and Efficacy of DA-9701 and Itopride Hydrochloride in Patients With Functional Dyspepsia | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Lee, Oh Young | - |
dc.identifier.doi | 10.5056/jnm14117 | - |
dc.identifier.scopusid | 2-s2.0-84934754662 | - |
dc.identifier.wosid | 000357708500014 | - |
dc.identifier.bibliographicCitation | JOURNAL OF NEUROGASTROENTEROLOGY AND MOTILITY, v.21, no.3, pp.414 - 422 | - |
dc.relation.isPartOf | JOURNAL OF NEUROGASTROENTEROLOGY AND MOTILITY | - |
dc.citation.title | JOURNAL OF NEUROGASTROENTEROLOGY AND MOTILITY | - |
dc.citation.volume | 21 | - |
dc.citation.number | 3 | - |
dc.citation.startPage | 414 | - |
dc.citation.endPage | 422 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.identifier.kciid | ART002016199 | - |
dc.description.journalClass | 1 | - |
dc.description.isOpenAccess | Y | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.description.journalRegisteredClass | kci | - |
dc.relation.journalResearchArea | Gastroenterology & Hepatology | - |
dc.relation.journalResearchArea | Neurosciences & Neurology | - |
dc.relation.journalWebOfScienceCategory | Gastroenterology & Hepatology | - |
dc.relation.journalWebOfScienceCategory | Clinical Neurology | - |
dc.subject.keywordPlus | QUALITY-OF-LIFE | - |
dc.subject.keywordPlus | PROKINETIC AGENT | - |
dc.subject.keywordPlus | NEPEAN DYSPEPSIA | - |
dc.subject.keywordPlus | CORYDALIS TUBER | - |
dc.subject.keywordPlus | LONG-TERM | - |
dc.subject.keywordPlus | SCALE | - |
dc.subject.keywordAuthor | Clinical trial | - |
dc.subject.keywordAuthor | DA-9701 | - |
dc.subject.keywordAuthor | Functional dyspepsia | - |
dc.subject.keywordAuthor | Itopride | - |
dc.identifier.url | https://www.jnmjournal.org/journal/view.html?doi=10.5056/jnm14117 | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
222, Wangsimni-ro, Seongdong-gu, Seoul, 04763, Korea+82-2-2220-1365
COPYRIGHT © 2021 HANYANG UNIVERSITY.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.